Mostra i principali dati dell'item

dc.creatorZerdes I., Tolia M., Nikolaou M., Tsoukalas N., Velentza L., Hajiioannou J., Mitsis M., Kyrgias G.en
dc.date.accessioned2023-01-31T11:38:23Z
dc.date.available2023-01-31T11:38:23Z
dc.date.issued2017
dc.identifier.issn11070625
dc.identifier.urihttp://hdl.handle.net/11615/80969
dc.description.abstractPurpose: Dermatomyositis (DM) represents an auto-immune inflammatory myopathy. In this review, we analyzed the incidence of DM as a clinical manifestation highlighting the peculiar clinical and treatment characteristics of this disease when occurring in the context of different malignancies. Methods: A systematic literature review was performed based on database search in PubMed/Medline and included English articles until December 2016. Results: In up to 20% of cases DM appears as a paraneoplastic syndrome associated with multiple malignancies such as ovarian, breast, prostate, lung, nasopharyngeal and colorectal cancer, and non-Hodgkin lymphomas. It can be presented either before, in the time, or after cancer diagnosis. Systemic sclerosis and mixed connective-tissue disease represent common coinciding disorders. Particular caution should be given in the radiotherapy because the microvascular endothelial radiation damage and autoimmune inflammatory collagen vascular disease caused by DM may be additive. There is a higher risk of late toxicity in the presence of other concurrent vascular diseases, including diabetes, hypertension or administration of chemotherapy. Prednisone represents the first-line treatment option but immunosuppressive drugs such as azathioprine and methotrexate may also be incorporated in the therapeutic armamentarium especially when DM is associated with malignancy. Intravenous immunoglobulin could be a promising alternative in prednisone-resistant cases. The effectiveness of therapies with antigen-specific agents such as monoclonal antibodies is currently under investigation. Conclusions: Timely diagnosis coupled with a treatment plan focused on muscular endurance and improvement of skin lesions and other symptoms offer a favorable response to therapy along with the achievement of a higher quality of life for these patients. © 2017 Zerbinis Publications. All rights reserved.en
dc.language.isoenen
dc.sourceJournal of B.U.ON.en
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85045548940&partnerID=40&md5=b45338190da02b46a639ee2bb2f3745a
dc.subjectazathioprineen
dc.subjectimmunoglobulinen
dc.subjectmethotrexateen
dc.subjectmonoclonal antibodyen
dc.subjectprednisoneen
dc.subjectantiinflammatory agenten
dc.subjectautoinflammatory diseaseen
dc.subjectbreast canceren
dc.subjectcancer radiotherapyen
dc.subjectcollagen diseaseen
dc.subjectcolonoscopyen
dc.subjectcolorectal canceren
dc.subjectcomputer assisted tomographyen
dc.subjectdermatomyositisen
dc.subjectdiabetes mellitusen
dc.subjectdisease associationen
dc.subjectdrug efficacyen
dc.subjecthumanen
dc.subjecthypertensionen
dc.subjectimmunosuppressive treatmenten
dc.subjectlaboratory testen
dc.subjectlung canceren
dc.subjectmixed connective tissue diseaseen
dc.subjectnasopharynx canceren
dc.subjectnonhodgkin lymphomaen
dc.subjectovary canceren
dc.subjectparaneoplastic syndromeen
dc.subjectphysical examinationen
dc.subjectprostate canceren
dc.subjectradiation injuryen
dc.subjectReviewen
dc.subjectrisk factoren
dc.subjectsystematic reviewen
dc.subjectsystemic sclerosisen
dc.subjectthorax radiographyen
dc.subjecttreatment responseen
dc.subjectvascular diseaseen
dc.subjectclinical trial (topic)en
dc.subjectdermatomyositisen
dc.subjectmeta analysisen
dc.subjectneoplasmen
dc.subjectparaneoplastic syndromeen
dc.subjectrandomized controlled trial (topic)en
dc.subjectAnti-Inflammatory Agentsen
dc.subjectClinical Trials as Topicen
dc.subjectDermatomyositisen
dc.subjectHumansen
dc.subjectNeoplasmsen
dc.subjectParaneoplastic Syndromesen
dc.subjectPrednisoneen
dc.subjectRandomized Controlled Trials as Topicen
dc.subjectRisk Factorsen
dc.subjectZerbinis Publicationsen
dc.titleHow can we effectively address the paraneoplastic dermatomyositis: Diagnosis, risk factors and treatment optionsen
dc.typeotheren


Files in questo item

FilesDimensioneFormatoMostra

Nessun files in questo item.

Questo item appare nelle seguenti collezioni

Mostra i principali dati dell'item